Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a study to characterize the pharmacokinetics as well as safety and tolerability of a single oral dose of LCZ696 200 mg in subjects with mild and moderate hepatic impairment compared to matched healthy subjects
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
All subjects:
Hepatic impairment subjects:
Exclusion criteria
All subjects:
Hepatic impairment subjects:
Healthy subjects:
Other protocol-defined inclusion/exclusion criteria may apply.
32 participants in 3 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal